Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact

  • LifeMine Therapeutics Inc, a drug discovery startup that uses genetically-encoded small molecules, has partnered with GlaxoSmithKline plc (NYSE:GSK) to discover and develop drugs from fungal genomes
  • GSK will bring three targets for LifeMine to run through its proprietary drug discovery platform, which scans for fungi that could be a match to create a small-molecule drug.
  • LifeMine will get $70 million from GSK through the deal, a sum that includes an equity investment in a $175 million funding round that has just closed.
  • The companies will share costs 50-50 during the discovery process and up to filing investigational new drug applications with the FDA. 
  • Then, GSK will take over and fund all development and commercialization efforts. 
  • “This is a transformative collaboration for LifeMine, and marks the first such agreement in genomic drug discovery from fungi, nature’s virtuoso medicinal chemists,” said Gregory Verdine, Ph.D., co-founder, chief executive officer and chief scientific officer of LifeMine. 
  • The companies did not disclose which indications or disease areas they would explore. LifeMine has initially focused on oncology and immune modulation, however. 
  • The deal also includes undisclosed milestones and royalties.
  • Price Action: GSK shares are down 0.51% at $43.01 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.